Press Release

Amyotrophic Lateral Sclerosis (ALS) Market to grow with a CAGR of 5.79%

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Amyotrophic Lateral Sclerosis (ALS) Market

 

According to TechSci Research report, “Global Amyotrophic Lateral Sclerosis (ALS) Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Amyotrophic Lateral Sclerosis (ALS) Market has valued at USD 663.15 million in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.79% through 2028.  This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market.

Fast-tracking and regulatory incentives can serve as drivers in the Global Amyotrophic Lateral Sclerosis (ALS) Market. ALS therapies that receive priority review status from regulatory authorities benefit from shorter review timelines. This can encourage pharmaceutical companies to develop treatments for ALS, as they can potentially bring their therapies to market more quickly and efficiently. ALS is classified as an orphan disease in many regions, including the United States and the European Union. This designation provides incentives to companies developing treatments for rare diseases, including reduced regulatory fees, tax credits, and extended market exclusivity. These incentives can make ALS drug development more economically viable. Regulatory incentives can attract research funding from both public and private sources. Knowing that a potential ALS therapy may receive regulatory support and expedited review can encourage investors and grant agencies to fund ALS research and development projects. By expediting the approval process and offering incentives, regulatory agencies foster an environment conducive to innovation in ALS research. This can lead to the development of novel therapies and treatment approaches. Fast-tracking and regulatory incentives can accelerate the availability of new ALS treatments to patients who desperately need them. This benefits ALS patients by providing access to potentially life-changing therapies sooner.

 Amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, is a progressive neurological disorder that leads to the deterioration of nerve cells responsible for controlling voluntary muscle movements. The hallmark features of this condition commonly include muscle twitching, stiffness, and a decline in arm and hand strength due to muscle atrophy.

In April 2023, Biogen Inc. has received approval from the U.S. Food and Drug Administration (FDA) for QALSODY, a 100 mg/15mL injection, as a treatment for amyotrophic lateral sclerosis (ALS) in adults with a mutation in the superoxide dismutase 1 (SOD1) gene. This approval is granted under accelerated approval, based on the observed reduction in plasma neurofilament light chain (NfL) levels in patients treated with QALSODY. The continued approval for this indication will depend on the confirmation of clinical benefits in subsequent trial(s). The ongoing Phase 3 ATLAS study for tofersen in individuals with presymptomatic SOD1-ALS will serve as the confirmatory trial. Neurofilament proteins, released from damaged neurons, serve as a marker for neurodegeneration.

The limited patient population in the Global Amyotrophic Lateral Sclerosis (ALS) Market is indeed a significant challenge. ALS is classified as a rare disease, also known as an orphan disease. Rare diseases typically have a small patient population, which can make it economically challenging for pharmaceutical companies to invest in research and drug development for such conditions. The small number of individuals affected by ALS results in a limited market size for ALS-related treatments and therapies. This can discourage pharmaceutical companies from allocating resources to ALS drug development, as the potential return on investment may be lower than for more prevalent diseases. Developing treatments for rare diseases like ALS can be cost-prohibitive. Clinical trials, regulatory approvals, and post-marketing surveillance are all resource-intensive processes. The limited patient population can make it difficult to recruit enough participants for clinical trials, further increasing development costs. Due to the limited patient population, pricing ALS treatments can be challenging. Pharmaceutical companies need to balance the costs of research, development, and manufacturing with the need to provide affordable access to patients. Striking this balance can be difficult in a small market.

 

Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on "Amyotrophic Lateral Sclerosis (ALS) Market

 

Global Amyotrophic Lateral Sclerosis (ALS) Market is segmented based on Drug Type, Treatment Type, End User, and by region

Based on the Drug Type, Global Amyotrophic Lateral Sclerosis (ALS) Market is segmented into Rilutek (Riluzole), Edaravone (Radicava). Edaravone, sold under the brand name Radicava, is a medication used in the treatment of Amyotrophic Lateral Sclerosis (ALS). It is one of the few drugs approved specifically for the treatment of ALS. Edaravone is used for the treatment of ALS in adult patients. ALS is a progressive neurodegenerative disease characterized by the degeneration of motor neurons in the brain and spinal cord, leading to muscle weakness, atrophy, and eventual loss of motor function. There is currently no cure for ALS, and treatment aims to slow down disease progression and improve patients' quality of life. Edaravone is administered intravenously (IV) in a medical setting. Typically, it is administered as a daily infusion over a period of 10 to 14 days, followed by a 14-day drug-free period. This treatment cycle is repeated, and the frequency and duration of treatment are determined by the healthcare provider based on the patient's condition and response to therapy.

Based on Region, North America held the largest share in the Global Amyotrophic Lateral Sclerosis (ALS) Market. ALS advocacy groups in North America have been effective in raising awareness about the disease, fundraising for research, and advocating for improved patient care. These efforts have mobilized resources and support for ALS research and treatment in the region. The regulatory environment in North America, particularly in the United States, is conducive to the development and approval of new drugs and therapies. The U.S. Food and Drug Administration (FDA) has processes for fast-tracking potential ALS treatments, which can accelerate their availability to patients. North America is home to several pharmaceutical and biotechnology companies with a focus on neurological disorders, including ALS. These companies have the expertise and resources to develop and commercialize ALS treatments. Despite challenges related to healthcare access and affordability, North America generally has good access to healthcare services, making it possible for ALS patients to receive medical care and treatments.

 

Some of the major companies operating in the Global Amyotrophic Lateral Sclerosis (ALS) Market include:

  • Sanofi S.A.
  • Brainstorm Cell Therapeutics Inc.
  • Biogen Inc.
  • Bausch Health Cos Inc.
  • F Hoffmann-la Roche Ltd
  • Ionis Pharmaceuticals
  • Mylan Pharma Inc.
  • Sun Pharmaceutical Industries Inc
  • Orion Pharma A/S
  • AB Science SA

 

Download Free Sample Report

Customers can also request 10% free customization on this report

 

“Certain areas, particularly in North America, are projected to exert significant demand for the treatment of Amyotrophic Lateral Sclerosis (ALS). The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global Amyotrophic Lateral Sclerosis (ALS) Market in the forecast period," said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

Amyotrophic Lateral Sclerosis (ALS) Market by Drug Type (Rilutek (Riluzole), Edaravone (Radicava)), By Treatment Type (Physical Therapy, Speech Therapy, Medication, Respiratory Therapy, Others), By End-Users (Hospitals & Clinics, Research and Academic institutes, others), By Region, By Competition Forecast & Opportunities, 2018-2028F has evaluated the future growth potential of Global Amyotrophic Lateral Sclerosis (ALS) Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Amyotrophic Lateral Sclerosis (ALS) Market.

 

 

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com

Relevant News